In a Phase I clinical trial (NCT02069145), the Fz8-Fc fusion protein Ipafricept (OMP-54F28) inhibited the competitive binding of Wnt ligands to Fzd8 and could be used in combination with sorafenib in patients with advanced HCC [119]. Here, FZD8 is linked to hepatocellular carcinoma.